Table 6

Group 2. Average annual mean change in score for pre-antidopaminergic and post-antidopaminergic takers and matched controls (SD in brackets)

Control group
(time 1)
(n=103)		Control group
(time 2)
(n=103)		P valueCohen’s dPre-antidopaminergic medication
(time 1)
(n=90)		Post-antidopaminergic
Medication
(time 2)
(n=90)		P valueCohen’s d
UHDRS total motor score2.4
(7.9)		2.7
(7.6)		0.8190.045.7
(11.2)		2.9
(9.2)		0.0790.27
UHDRS total chorea score0.4
(4.5)		1
(4.2)		0.3440.141.1
(4.7)		−0.5*
(5.5)		0.0360.31
UHDRS saccade initiation0.4
(1.4)		0.1
(1.4)		0.1000.210.6
(1.5)		0.03*
(1.7)		0.0200.35
Irritability
(PBA)		0.4
(4)		0.6
(3.4)		0.7450.050.1
(6.2)		−1.8
(6.2)		0.0650.31
Depression
(PBA)		−0.1
(4.1)		−0.1
(4.5)		0.96200.8
(6.2)		−0.2
(6.7)		0.5080.2
Apathy
(PBA)		0.02
(2.9)		0.3
(3.3)		0.4740.090.3
(4)		0.9
(4.9)		0.3960.13
Total composite cognitive z-score0.4
(3.9)		−0.3
(4)		0.1990.180.8
(3.4)		−0.7***
(3.4)		0.0010.44
TFC score−0.6
(1.3)		−0.4
(1.6)		0.4830.13−0.9
(1.8)		−1
(1.6)		0.6640.05
UHDRS independence scale−3.1
(7.6)		−1.8
(9.5)		0.30.15−5.2
(9.5)		−3.6
(7.3)		0.1830.18

  • P values are from paired t-tests.

  • *Indicates a significant difference (p<0.005) when compared with the control non-antidopaminergic medication group.

  • †Indicates a significant difference (p<0.001) when compared with the control non-antidopaminergic medication group.

  • PBA, problems behavioural assessment; TFC, total functional capacity; UHDRS, Unified Huntington Disease Rating Scale.